Needham & Company LLC Boosts Hims & Hers Health (NYSE:HIMS) Price Target to $42.00

Hims & Hers Health (NYSE:HIMS) had its price objective raised by equities research analysts at Needham & Company LLC from $35.00 to $42.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 32.03% from the stock’s current price.

HIMS has been the topic of a number of other research reports. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. UBS Group set a $23.00 target price on Hims & Hers Health in a research report on Friday, May 22nd. BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $25.00 price target on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Finally, Jefferies Financial Group set a $24.50 price objective on shares of Hims & Hers Health in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average target price of $31.90.

Hims & Hers Health Stock Up 0.7%

HIMS stock opened at $31.81 on Tuesday. The company’s 50 day moving average is $31.94 and its 200 day moving average is $26.07. The stock has a market cap of $7.36 billion, a price-to-earnings ratio of -353.44, a price-to-earnings-growth ratio of 88.90 and a beta of 2.40. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $65.30.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the previous year, the firm earned $0.20 earnings per share. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. Sell-side analysts predict that Hims & Hers Health will post 0.03 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 23,726 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the transaction, the insider owned 181,861 shares in the company, valued at approximately $6,365,135. This trade represents a 11.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the sale, the chief operating officer owned 432,124 shares of the company’s stock, valued at $13,611,906. This represents a 3.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 83,126 shares of company stock valued at $2,711,339. 11.76% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

Institutional investors have recently modified their holdings of the company. Versant Capital Management Inc grew its stake in shares of Hims & Hers Health by 801.2% in the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after purchasing an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth approximately $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth approximately $28,000. Finally, Bogart Wealth LLC increased its stake in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue rose 38.2% year over year to approximately $753.2 million, exceeding the roughly $698.9 million analyst consensus. The company also cited strong subscriber growth and broader personalized healthcare offerings. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion. Third-quarter revenue guidance of $880 million-$900 million also exceeds the approximately $845.9 million consensus estimate, signaling continued demand. Hims & Hers Boosts Revenue Target, Swings to Second-Quarter Loss
• Neutral Sentiment: Investor attention is focused on the company’s investment cycle, particularly its branded GLP-1 offering and international expansion. These initiatives could support long-term growth but may pressure near-term margins and earnings.
• Negative Sentiment: The company reported a second-quarter loss of $0.37 per share, far worse than the approximately $0.05 loss expected by analysts and sharply below the $0.17 profit reported a year earlier. The earnings miss overshadowed the revenue beat and higher forecast. Hims & Hers stock drops despite higher guidance
• Negative Sentiment: Several law firms announced investigations into potential securities-law or fiduciary-duty violations involving Hims & Hers directors and officers. The investigations are allegations rather than established findings, but they add reputational and legal uncertainty. Hims & Hers investor alert

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.